Gliomas are the deadliest and most common of primary brain tumors, and they currently lack effective treatments. They grow relentlessly, often causing profound neurological impairments as the enlarging tumor impinges on vital brain structures. Peritumoral seizures are an early symptom and up to 80% of individuals with glioma experience at least one seizure during the course of their illness 1,2 . Approximately one-third of individuals develop recurrent seizures, known as tumorassociated epilepsy 3 , and these can be refractory to traditional antiepileptic medication 2 . The etiology of tumor-associated seizures and their relationship with tumor growth is poorly understood. Increased glutamate levels have been implicated in numerous seizure disorders, and glutamate can reach neurotoxic levels immediately preceding and during spontaneous seizures 4 . Previous studies conducted in both humans with glioma and glioma-implanted rodents have suggested that epileptiform activity originates within the peritumoral border, 1-2 mm away from the tumor mass, where invading tumor cells surround neurons 5-7 . A recent clinical study involving nine glioma patients examined glutamate concentrations in central nervous system dialysates taken from peritumoral cortex and from uninvolved brain, and found peritumoral glutamate concentrations above 100 µM, 100-fold higher than levels in uninvolved brain 8 . This increase in peritumoral glutamate may be ascribed to the activity of system x c − , a Na + -independent cystine-glutamate transporter [9] [10] [11] . System x c − is a heterodimeric transporter consisting of a catalytic (xCT) and a regulatory (CD98) subunit, both of which are highly expressed by glioma cells 12 . System x c − imports cystine for the synthesis of the antioxidant glutathione, and cystine uptake is coupled to glutamate release 13, 14 .
Gliomas are the deadliest and most common of primary brain tumors, and they currently lack effective treatments. They grow relentlessly, often causing profound neurological impairments as the enlarging tumor impinges on vital brain structures. Peritumoral seizures are an early symptom and up to 80% of individuals with glioma experience at least one seizure during the course of their illness 1, 2 . Approximately one-third of individuals develop recurrent seizures, known as tumorassociated epilepsy 3 , and these can be refractory to traditional antiepileptic medication 2 . The etiology of tumor-associated seizures and their relationship with tumor growth is poorly understood. Increased glutamate levels have been implicated in numerous seizure disorders, and glutamate can reach neurotoxic levels immediately preceding and during spontaneous seizures 4 . Previous studies conducted in both humans with glioma and glioma-implanted rodents have suggested that epileptiform activity originates within the peritumoral border, 1-2 mm away from the tumor mass, where invading tumor cells surround neurons [5] [6] [7] . A recent clinical study involving nine glioma patients examined glutamate concentrations in central nervous system dialysates taken from peritumoral cortex and from uninvolved brain, and found peritumoral glutamate concentrations above 100 µM, 100-fold higher than levels in uninvolved brain 8 . This increase in peritumoral glutamate may be ascribed to the activity of system x c − , a Na + -independent cystine-glutamate transporter [9] [10] [11] . System x c − is a heterodimeric transporter consisting of a catalytic (xCT) and a regulatory (CD98) subunit, both of which are highly expressed by glioma cells 12 . System x c − imports cystine for the synthesis of the antioxidant glutathione, and cystine uptake is coupled to glutamate release 13, 14 .
In this study, we hypothesize that glutamate release from gliomas through system x c − activates glutamate receptors on peritumoral neurons, leading to neuronal hyperexcitability and epileptic activity. To elucidate the possible relationship between tumor-mediated glutamate release and epileptic activity, we modeled the disease in glioma-bearing mice to permit both in vivo and in situ analysis. Using electroencephalogram (EEG) recordings, we found that abnormal EEG activity develops in tumor-bearing mice but not in controls. This activity presents as short-duration abnormal EEG events that typically increase in frequency as the tumor progresses. Brain slices prepared from these mice show enhanced glutamate release and peritumoral neuronal hyperexcitability. This excitability spreads into the tumor-associated brain, as shown by optical recordings. Notably, pharmacological inhibition of system x c − -mediated glutamate release from gliomas by SAS, a US Food and Drug Administration (FDA)approved drug, inhibits peritumoral hyperexcitability and reduces epileptic event frequency in tumor-bearing mice.
RESULTS

Glioma-bearing mice show recurrent epileptic activity
We adopted a widely used mouse model of glioma 15, 16 to study the relationship between glutamate release from glioma cells and the development of epileptic activity in vivo. Specifically, we implanted either the U251-GFP human glioma cell line or the human glioma xenografts GBM12 and GBM22 intracranially into mice. The glioma xenografts originated from two patient biopsies and were propagated by ectopic implantation into the flanks of nude mice 17 . These xenografts are currently considered the best available glioma model Epileptic seizures are a common and poorly understood comorbidity for individuals with primary brain tumors. To investigate peritumoral seizure etiology, we implanted human-derived glioma cells into severe combined immunodeficient mice. Within 14-18 d, glioma-bearing mice developed spontaneous and recurring abnormal electroencephalogram events consistent with progressive epileptic activity. Acute brain slices from these mice showed marked glutamate release from the tumor mediated by the system x c − cystine-glutamate transporter (encoded by Slc7a11). Biophysical and optical recordings showed glutamatergic epileptiform hyperexcitability that spread into adjacent brain tissue. We inhibited glutamate release from the tumor and the ensuing hyperexcitability by sulfasalazine (SAS), a US Food and Drug Administration-approved drug that blocks system x c − . We found that acute administration of SAS at concentrations equivalent to those used to treat Crohn's disease in humans reduced epileptic event frequency in tumor-bearing mice compared with untreated controls. SAS should be considered as an adjuvant treatment to ameliorate peritumoral seizures associated with glioma in humans.
system because they retain their intrinsic gene and protein expression and invasive properties 17, 18 . We initially validated tumor growth after intracranial implantation of U251 cells engineered to express firefly-luciferase (U251-ffluc) by imaging cell bioluminescence using a Xenogen IVIS system ( Supplementary Fig. 1 ). In agreement with published reports 13 , tumor size was similar between mice and correlated positively with bioluminescence intensity. Our histological evaluation of the resulting tumor showed invasion into the surrounding brain, as is commonly observed in the human disease ( Supplementary Fig. 2 ). We validated expression of xCT, the catalytic subunit of system x c − , in all tumor types by western blotting, and, using 3 H-glutamate tracer studies, we showed functional system x c − activity that was SASsensitive and Na + -independent ( Supplementary Fig. 3 ).
We placed intracranial EEG electrodes in 86 glioma-implanted mice and 14 sham-operated control mice (sham) 1 week after glioma cell implantation. One week later, we conducted continuous EEG/video monitoring for 10-14 d. We observed spontaneous, recurring and unprovoked abnormal EEG activity in 37.2% of glioma-bearing mice (n = 32) ( Fig. 1a) . Event duration was between 0.5 and 1 s (0.538 s ± 0.113, n = 400) ( Fig. 1a) , and events showed a discrete rise in the power spectrum at 12-15 Hz (Fig. 1b ). Activity increased progressively over time ( Fig. 1c) . We detected no abnormal activity in any sham mouse. Although three mice showed epileptic activity that progressed to tonic-clonic convulsions, the behavioral phenotype typically associated with these EEG events was subtle; mice showed freezing behavior with facial automatisms and head tremor, a finding consistent with a previous study in glioma-bearing rats 7 . We found that EEG activity was similar in duration, amplitude and frequency to that described for post-traumatic epilepsy in humans and rodents 19 ; thus, here we refer to this as epileptic activity 19 .
Glutamate release is inhibited by blocking system x c −
We hypothesized that the epileptic activity in glioma-bearing mice was a result of glutamate release by the tumor via the system x c − transporter. We prepared acute cortical slices from seven sham mice and from nine U251-GFP-bearing mice, in which the presence of tumor was confirmed by EGFP fluorescence (Fig. 1d) . Glutamate release into the bath was measured from individual slices (three slices per mouse) in the presence of 100 µM cystine by tandem HPLC-mass spectrometry. Glioma-bearing slices showed a time-dependent increase in glutamate compared with sham (control) slices, with concentrations increasing to 5 µM after 2 h of incubation (0.5 h: 0.3675 ± 0.07 control, 0.735 ± 0.111 tumor; 1 h: 0.7941 ± 0.15 control, 1.745 ± 0.33 tumor; 2 h: 2.242 ± 0.33 control, 5.059 ± 1.01 tumor) (*P < 0.05) ( Fig. 1e) . Because of glutamate dilution in the bath and astrocytic uptake in tumor-free areas, the absolute concentration within peritumoral tissue is likely to be higher. To show that glutamate release occurred through system x c − , we incubated an identical number of slices from the same animals in a bath containing 250 µM SAS. SAStreated slices released significantly less glutamate (1 h: 0.7984 ± 0.15; 2 h: 2.199 ± 0.36) (**P < 0.01) ( Fig. 1e) . In sham slices, we found that glutamate release was unaffected by SAS, suggesting that system x c − does not contribute substantially to glutamate release in tumor-free brain. 
Gliomas induce spreading epileptiform activity
We next examined whether peritumoral brain shows abnormal spontaneous activity. We placed an extracellular field recording electrode in cortical layers 2 and 3, 0.5-1.5 mm from the tumor, and in comparable regions of sham cortex ( Fig. 2a-c) . We observed short spontaneous paroxysmal discharges (100-500 ms) in 23% of slices from 12 U251-GFP glioma-bearing mice in Mg 2+ -containing artificial cerebrospinal fluid (ACSF) (n = 43), yet these were absent in slices from five sham mice (n = 27) ( Fig. 2d) . We validated slice viability by recording evoked activity in response to field electrode stimulation in deeper layer 4 (data not shown).
To further assess peritumoral neuronal excitability, we obtained whole-cell patch-clamp recordings from neurons in slices from 19 glioma-bearing and 4 sham mice. We enhanced excitability by removing extracellular Mg 2+ that normally blocks N-methyl-d-aspartate (NMDA) receptors (NMDARs) 20, 21 . We conducted all recordings in 100 µM cystine to ensure sufficient substrate availability for system x c − . Peritumoral neurons showed a significantly shorter latency to the first epileptiform discharge in slices containing U251-GFP (12 min ± 2, n = 16, *P < 0.05), GBM12 (9 min ± 2.5, n = 7, *P < 0.05) or GBM22 (8.5 min ± 1.3, n = 13, *P < 0.05) tumors ( Fig. 3a-c) compared with sham slices (26 min ± 3.5, n = 16). Event duration was similar between sham slices (7 s ± 2, n = 11) slices containing tumors from U251-GFP (7.8 s ± 1.7, n = 12, P > 0.05), GBM12 (8.9 s ± 0.7, n = 5, P > 0.05) and GBM22 (13 s ± 3, n = 8, P > 0.05) ( Fig. 3d) .
To evaluate peritumoral cortical network hyperexcitability, we used the voltage-sensitive dye RH414 with a Neuroplex 464 diode array to visualize the spatial-temporal propagation of voltage after brief electrical stimulation, as previously described 22 . We placed the stimulating electrode in acute cortical slices within 0.5-1.5 mm of U251-GFP tumors and in comparable anatomical areas within sham slices and visualized them with pseudocolored images corresponding to the degree of membrane depolarization. Visual observation of array data revealed more a pronounced spread of depolarization in gliomabearing slices compared with sham slices in response to 80 µA of stimulating current (Fig. 4a) . To quantify these differences, we measured the amplitude, voltage spread, and response duration in slices from U251-GFP-implanted (n = 4) and sham-operated mice (n = 4). We found that response amplitude and duration were not significantly different in slices at 80 µA stimulation (data not shown). However, the percentage of activated diodes registering a voltage change above baseline was significantly greater in glioma-bearing slices (30.17% ± 1.95, n = 11) compared with sham slices (18.77% ± 1.88, n = 8, ***P < 0.001), consistent with an increased area of excitability (Fig. 4b) .
Properties of peritumoral layer 2 and 3 pyramidal cells Peritumoral hyperexcitability may result from alterations of intrinsic neuronal properties, such as resting membrane potential (RMP) or input resistance. However, our findings showed that RMP (~−60 mV) and input resistance, as assessed by whole-cell current-clamp recordings in visually identified layer 2 and 3 pyramidal cells (confirmed by biocytin staining), were similar between all slices from glioma-bearing animals (n = 43) and controls (n = 7) ( Fig. 4c,d) . Peritumoral neuronal input resistance from slices containing U251-GFP (150 ± 18 MΩ, n = 60, P > 0.05), GBM12 (113 ± 9 MΩ, n = 10, P > 0.05), or GBM22 (164 ± 12 MΩ, n = 41, P > 0.05) was equivalent to slices from sham-operated mice (155 ± 18 MΩ, n = 26, P > 0.05) ( Fig. 4c) . However, we found that in peritumoral neurons, the number of action potentials fired in response to 20, 40, 60 and 80 pA current injections was significantly greater than in sham neurons (20 pA: *P < 0.05; 40 pA: *P < 0.05; 60 pA: *P < 0.05; 80 pA: *P < 0.05) (Fig. 4e,f) , indicating a lowered excitability threshold.
Blocking system x c − eliminates epileptiform activity To determine whether glutamate release from system x c − contributes to epileptiform activity in peritumoral brain, we obtained whole-cell patch clamp recordings from peritumoral neurons in acute brain slices from three U251-GFP (n = 7), three GBM12 (n = 6) and three GBM22 (n = 5) implanted mice. We observed that epileptiform activity was readily induced in Mg 2+ -free solution in all tumor-bearing slices, as shown for representative examples of GBM12 and GBM22 peritumoral neurons (Fig. 5a,b) . Blocking system x c − -mediated glutamate release with 250 µM SAS decreased the mean duration of events lasting longer than 3 s (U251-GFP: 9 ± 0.6 s; U251-GFP + SAS: 0.8 ± 0.2 s, **P < 0.01; GBM12: 11 ± 2 s; GBM12 + SAS: 1 ± 0.2 s, **P < 0.01; GBM22: 13 ± 2 s; GBM22 + SAS 1.4 ± 0.4 s, **P < 0.01) ( Fig. 5a-c) . The remaining events in SAS were of short duration and were reduced in amplitude to 44 ± 6% compared with the amplitude prior to drug application. All remaining activity was completely abolished after the application of 50 µM 2-amino-5-phosphonopentanoic acid (APV), an NMDA antagonist ( Fig. 5a-c) . All the peritumoral neurons we recorded were located close to tumor masses ( Fig. 5d) .
These data indicate that peritumoral neurons have a reduced excitability threshold compared to neurons from sham animals, presumably as a result of elevated levels of peritumoral glutamate. Consistent with this, bath application of 20 µM glutamate in the presence of Mg 2+ induced epileptiform activity in 66% of U251-GFP glioma-bearing slices (n = 9) from four mice, but not in slices (n = 6) from three sham-operated mice ( Supplementary  Fig. 4) . Loss of γ-aminobutyric acid (GABA)ergic inhibition may also contribute to abnormal excitability; bicuculline (BIC), a GABA A receptor antagonist, has been shown to facilitate excitatory synchronization 23 . Whole-cell recordings conducted in the presence of 10 µM BIC showed that neurons in slices (n = 6) from three sham mice showed typical spontaneous excitatory postsynaptic currents without development of epileptiform activity. However, spontaneous epileptiform events were observed in 50% of peritumoral neurons in 11 slices treated with BIC from three U251-GFP-implanted mice, thereby suggesting changes in both excitatory and inhibitory properties in these neurons (Supplementary Fig. 5 ).
SAS decreases epileptic activity in mice
Our biophysical data show that peritumoral epileptiform activity is inhibited by blocking system x c − -mediated glutamate release with SAS. If glutamate release via system x c − causes epileptic activity in vivo, we hypothesized that SAS treatment could reduce or eliminate this activity in glioma-bearing mice. Fourteen U251-GFP-implanted mice showing epileptic activity were injected intraperitoneally (i.p.) twice daily for 3 d with either 1 ml of PBS (n = 6) or 1 ml of 8 mg ml −1 SAS (n = 8), an equivalent dose to that typically taken by Crohn's disease patients. We analyzed EEGs recorded 4 h immediately before and 4 h immediately after treatment. We found that the frequency of activity in SAS-treated mice was significantly decreased in the 4 h after (4.25 ± 2.41) compared with the 4 h before treatment (7.50 ± 3.41, **P < 0.01) ( Fig. 6a) , but that it was unaffected by PBS treatment (before: 7.23 ± 2.09; after: 6.73 ± 2.24, P > 0.05). A detailed hourly analysis of treatment shows the most profound drop in frequency within the first 2 h after treatment (1h: SAS: 0.356 ± 0.091; PBS: 1.733 ± 0.22; ***P < 0.001; 2h: SAS: 1.00 ± 0.135; PBS: 1.77 ± 0.005, ***P < 0.001) (Fig. 6b) . These results reflect the previously reported, relatively short biological half-life (~80 min) of SAS in the plasma of treated mice 24 . Mice did not develop a tolerance to SAS; repeated dosing showed similar efficacy suppressing epileptic activity, as shown for one representative mouse (Fig. 6c) .
DISCUSSION
Recurring seizures, often referred to as tumor-associated epilepsy, are a well-documented yet poorly understood comorbidity affecting approximately one-third of individuals with glioma 3 . By modeling the disease in mice implanted with three different patient-derived gliomas, we show through EEG and video recording that 37.2% develop spontaneous, recurrent, abnormal EEG activity. Biophysical recordings conducted on acute cortical slices from these mice show that peritumoral neuronal hyperexcitability is attributable to glutamate release by glioma cells via the system x c − cystine-glutamate transporter. We measured glutamate released from glioma-bearing slices in the 5 µM range, which is sufficient to activate neuronal glutamate receptors 25 , although the actual glutamate concentration to which these peritumoral neurons are exposed is likely to be much higher than what we measured in our assays because of dilution into the medium and astrocytic reuptake. A recent study done in ambulatory glioma patients measured peritumoral glutamate concentrations in excess of 100 µM (ref. 8) . Peritumoral astrocytes that would normally be effective in removing and catabolizing extracellular glutamate 26 seem to be overwhelmed by glutamate release from the tumor.
Peritumoral neurons showed a lowered threshold for action potential generation and a reduced latency to development of epileptiform activity after Mg 2+ removal compared with neurons recorded in sham-operated mice. We found that this activity was glutamate receptor-dependent and completely blocked by APV. Application of 20 µM glutamate in the presence of Mg 2+ induced hyperexcitability in peritumoral but not sham neurons. Therefore, we suggest that the reduced activation threshold for peritumoral neurons can be largely attributed to an enhanced glutamatergic drive with a contribution of reduced GABAergic inhibition. Further studies will need to examine changes in peritumoral transmitter receptors in greater detail.
Elevated levels of extracellular glutamate have previously been implicated in development of seizures and epilepsy [27] [28] [29] , although in those studies the glutamate source was neuronal. In glioma-bearing mice (our study) and rats 30 , the primary glutamate source is the growing tumor. We show in mice that glutamate release by gliomas is through system x c − because it is Na + -independent, cystine-dependent and blocked by SAS. Previous studies similarly show system x c − -mediated glutamate release from gliomas in vitro 9 , in situ 31 and in vivo 32 , leading to tumor growth 13 , tumor-associated excitotoxicity 32 and edema 32, 33 .
We found that SAS treatment reduced epileptic activity in gliomabearing mice, implicating glutamate release via system x c − in the generation of tumor-associated epileptic events. System x c − may also generate epileptic events in humans. Together with previous studies, our findings establish that system x c − is a viable new target for seizure treatments. The effects of SAS are encouraging, particularly because SAS is an FDA-approved drug with well-described, tolerable side effects that support its use as adjuvant treatment for peritumoral epilepsy. A clinical trial conducted on several end-stage glioblastoma patients with poor neurological status used SAS to inhibit nuclear factor κB; they reported no significant impact on tumor growth 34 . However, this study enrolled a severely ill, neurologically impaired patient population and did not assess antiepileptic effects 34 . Seizures often present early in disease progression and particularly affect patients with low-grade, slow-growing tumors that can become refractory to traditional antiepileptic drugs; accordingly, these patients are the most likely to benefit from SAS treatment 1 . Clearly, our findings suggest that a well-designed clinical study of SAS treatment for low-grade glioma patients is warranted.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
